Article Details
Retrieved on: 2022-08-30 15:32:24
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In September 2017, the Patented Medicine Prices Review Board (PMPRB) decided that Alexion's SOLIRIS (eculizumab) was sold at an excessive price.
Article found on: www.jdsupra.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here